miRNA在粘液性卵巢癌诊断及预后中的作用进展
The Role of miRNA in the Diagnosis and Prognosis of Mucinous Ovarian Cancer
DOI: 10.12677/acm.2025.15102891, PDF,   
作者: 邬舒琪, 路会侠*：大理大学临床医学院，云南 大理；大理大学临床医学院妇产科教研室，云南 大理
关键词: 粘液性卵巢癌；MiRNA；诊断；预后；Mucinous Ovarian Cancer； MiRNA； Diagnosis； Prognosis
摘要: 粘液性卵巢癌(mucinous ovarian cancer, MOC)是上皮性卵巢癌(epithelial ovarian cancer, EOC)的一种特殊类型，早期诊断对改善MOC患者预后具有重要意义。微小核糖核酸(microRNA, miRNA)可反映肿瘤负荷，miRNA过表达能导致抑癌基因表达下降、肿瘤发生。miR-194、miR-192等在MOC中上调并影响预后，MOC的miRNA表达在不同亚型之间不同，特定miRNA与组织学类型相关，可以作为独立诊断的生物标志物；miRNA通过调控细胞周期、抑制上皮–间充质转化(EMT)等多种途径调控MOC的预后，miRNA作为新的诊断和预后标记物，为MOC的诊断和治疗提供了新思路和策略。
Abstract: Mucinous ovarian cancer (MOC) is a special type of epithelial ovarian cancer (EOC). Early diagnosis is of great significance in improving the prognosis of patients with MOC. microRNA (miRNA) can reflect tumor burden, and overexpression of miRNA can lead to decreased expression of tumor suppressor genes and tumorigenesis. miR-194 and miR-192 are upregulated in MOC and affect prognosis. miRNA expression in MOC varies among different subtypes, and specific mirnas are correlated with histological types and can be used as biomarkers for independent diagnosis. miRNA regulates the prognosis of MOC by regulating cell cycle and inhibiting epithelial mesenchymal transition (EMT). As a new diagnostic and prognostic marker, miRNA provides new ideas and strategies for the diagnosis and treatment of MOC.
文章引用：邬舒琪, 路会侠. miRNA在粘液性卵巢癌诊断及预后中的作用进展[J]. 临床医学进展, 2025, 15(10): 1342-1348. https://doi.org/10.12677/acm.2025.15102891

参考文献

[1] Armand-Labit, V. and Pradines, A. (2017) Circulating Cell-Free MicroRNAs as Clinical Cancer Biomarkers. Biomolecular Concepts, 8, 61-81. [Google Scholar] [CrossRef] [PubMed]
[2] Fridrichova, I., Kalinkova, L., Karhanek, M., Smolkova, B., Machalekova, K., Wachsmannova, L., et al. (2020) miR-497-5p Decreased Expression Associated with High-Risk Endometrial Cancer. International Journal of Molecular Sciences, 22, Article 127. [Google Scholar] [CrossRef] [PubMed]
[3] Hisamatsu, T., McGuire, M., Wu, S.Y., Rupaimoole, R., Pradeep, S., Bayraktar, E., et al. (2019) PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 18, 162-172. [Google Scholar] [CrossRef] [PubMed]
[4] Ali, F.T., Soliman, R.M., Hassan, N.S., Ibrahim, A.M., El-Gizawy, M.M., Mandoh, A.A.Y., et al. (2022) Sensitivity and Specificity of MicroRNA-204, CA125, and CA19.9 as Biomarkers for Diagnosis of Ovarian Cancer. PLOS ONE, 17, e0272308. [Google Scholar] [CrossRef] [PubMed]
[5] Liang, C.Y., Li, Z.Y., Gan, T.Q., et al. (2020) Downregulation of Hsa-MicroRNA-204-5p and Identification of Its Potential Regulatory Network in Non-Small Cell Lung Cancer: RT-qPCR, Bioinformatic-and Meta-Analyses. Respiratory Research, 21, Article No. 60.
[6] Di Fiore, R., Drago-Ferrante, R., Suleiman, S., Calleja, N. and Calleja-Agius, J. (2024) The Role of MicroRNA-9 in Ovarian and Cervical Cancers: An Updated Overview. European Journal of Surgical Oncology, 51, Article 108546. [Google Scholar] [CrossRef] [PubMed]
[7] Aichen, Z., Kun, W., Xiaochun, S. and Lingling, T. (2021) LncRNA FGD5-AS1 Promotes the Malignant Phenotypes of Ovarian Cancer Cells via Targeting miR-142-5p. Apoptosis, 26, 348-360. [Google Scholar] [CrossRef] [PubMed]
[8] Kobayashi, M., Salomon, C., Tapia, J., Illanes, S.E., Mitchell, M.D. and Rice, G.E. (2014) Ovarian Cancer Cell Invasiveness Is Associated with Discordant Exosomal Sequestration of Let-7 miRNA and miR-200. Journal of Translational Medicine, 12, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[9] Samia, H., Lasheen, A., Abdelrahman, A., Al-Karamany, A., Sameh, R. and Algazeery, A. (2022) Association between miR-196a-2 Gene Polymorphism and Ovarian Cancer Prognosis in Egyptian Females. Asian Pacific Journal of Cancer Prevention, 23, 1761-1768. [Google Scholar] [CrossRef] [PubMed]
[10] Biray, C.A. and Yusuf, B. (2014) Use of MicroRNAs in Personalized Medicine. Methods in Molecular Biology (Clifton, N.J.), 1107, 311-325.
[11] Meng, X.D., Müller, V., Milde-Langosch, K., et al. (2016) Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. Advances in Experimental Medicine and Biology, 2016, 9243-9248.
[12] Zhu, Z., Chen, Z., Wang, M., Zhang, M., Chen, Y., Yang, X., et al. (2022) Detection of Plasma Exosomal MiRNA-205 as a Biomarker for Early Diagnosis and an Adjuvant Indicator of Ovarian Cancer Staging. Journal of Ovarian Research, 15, Article No. 27. [Google Scholar] [CrossRef] [PubMed]
[13] Delek, F.S.P., Tunçer, Ş.B., Ödemiş, D.A., Erciyas, S.K., Erdoğan, Ö.Ş., Saip, P., et al. (2024) miR-3653-3p Expression in PBMCs: Unveiling the Diagnostic Potential for Ovarian Cancer. Biochemical Genetics, 63, 2172-2189. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, M.J., Mao, X.M. and Wang, S.Y. (2021) Clinical Significance of miR-139-5p and FGF2 in Ovarian Cancer. Journal of BUON, 26, 663-669.
[15] Zuo, Y., Zheng, W., Tang, Q., Liu, J., Wang, S. and Xin, C. (2021) miR-576-3p Overexpression Enhances Cisplatin Sensitivity of Ovarian Cancer Cells by Dysregulating PD-L1 and Cyclin D1. Molecular Medicine Reports, 23, Article No. 81. [Google Scholar] [CrossRef] [PubMed]
[16] Lili, Y. and Yu, W. (2022) Extracellular Vesicles Derived from M2-Polarized Tumor-Associated Macrophages Promote Immune Escape in Ovarian Cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 Axis. Cancer Immunology, Immunotherapy, 72, 743-758.
[17] Feng, S., Sun, H. and Zhu, W. (2020) miR-92 Overexpression Suppresses Immune Cell Function in Ovarian Cancer via LATS2/YAP1/PD-L1 Pathway. Clinical and Translational Oncology, 23, 450-458. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, R., Ye, H., Yang, B., Ao, M., Yu, X., Wu, Y., et al. (2023) M6a-modified Circnfix Promotes Ovarian Cancer Progression and Immune Escape via Activating IL-6R/JAK1/STAT3 Signaling by Sponging miR-647. International Immunopharmacology, 124, Article 110879. [Google Scholar] [CrossRef] [PubMed]
[19] Zhuang, R., Bai, X. and Liu, W. (2019) MicroRNA-23a Depletion Promotes Apoptosis of Ovarian Cancer Stem Cell and Inhibits Cell Migration by Targeting DLG2. Cancer Biology & Therapy, 20, 897-911. [Google Scholar] [CrossRef] [PubMed]
[20] Lheureux, S., Gourley, C., Vergote, I. and Oza, A.M. (2019) Epithelial Ovarian Cancer. The Lancet, 393, 1240-1253. [Google Scholar] [CrossRef] [PubMed]
[21] Yoshikawa, N., Kajiyama, H., Mizuno, M., Shibata, K., Kawai, M., Nagasaka, T., et al. (2014) Clinicopathologic Features of Epithelial Ovarian Carcinoma in Younger vs. Older Patients: Analysis in Japanese Women. Journal of Gynecologic Oncology, 25, 118-123. [Google Scholar] [CrossRef] [PubMed]
[22] Wang, J., Paris, P.L., Chen, J., Ngo, V., Yao, H., Frazier, M.L., et al. (2015) Next Generation Sequencing of Pancreatic Cyst Fluid MicroRNAs from Low Grade-Benign and High Grade-Invasive Lesions. Cancer Letters, 356, 404-409. [Google Scholar] [CrossRef] [PubMed]
[23] Dolivet, E., Gaichies, L., Jeanne, C., Bazille, C., Briand, M., Vernon, M., et al. (2023) Synergy of the MicroRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors. International Journal of Molecular Sciences, 24, Article 16016. [Google Scholar] [CrossRef] [PubMed]
[24] Agostini, A., Brunetti, M., Davidson, B., Tropé, C.G., Eriksson, A.G.Z., Heim, S., et al. (2018) The MicroRNA miR-192/215 Family Is Upregulated in Mucinous Ovarian Carcinomas. Scientific Reports, 8, Article No. 11069. [Google Scholar] [CrossRef] [PubMed]
[25] Lee, H., Park, C.S., Deftereos, G., Morihara, J., Stern, J.E., Hawes, S.E., et al. (2012) MicroRNA Expression in Ovarian Carcinoma and Its Correlation with Clinicopathological Features. World Journal of Surgical Oncology, 10, Article No. 174. [Google Scholar] [CrossRef] [PubMed]
[26] Velle, A., Pesenti, C., Grassi, T., Beltrame, L., Martini, P., Jaconi, M., et al. (2022) A Comprehensive Investigation of Histotype-Specific MicroRNA and Their Variants in Stage I Epithelial Ovarian Cancers. International Journal of Cancer, 152, 1989-2001. [Google Scholar] [CrossRef] [PubMed]
[27] Chen, X., Chen, S., Xiu, Y., Sun, K., Zong, Z. and Zhao, Y. (2015) Rhoc Is a Major Target of MicroRNA-93-5p in Epithelial Ovarian Carcinoma Tumorigenesis and Progression. Molecular Cancer, 14, Article No. 31. [Google Scholar] [CrossRef] [PubMed]
[28] Dai, F., Zhang, Y. and Chen, Y. (2014) Involvement of miR-29b Signaling in the Sensitivity to Chemotherapy in Patients with Ovarian Carcinoma. Human Pathology, 45, 1285-1293. [Google Scholar] [CrossRef] [PubMed]
[29] Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Ravaggi, A., Martini, P., et al. (2013) MiRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities. Clinical Cancer Research, 19, 4114-4123. [Google Scholar] [CrossRef] [PubMed]
[30] Pal, K.M., Jaiswar, P.S., Dwivedi, N.V., et al. (2015) MicroRNA: A New and Promising Potential Biomarker for Diagnosis and Prognosis of Ovarian Cancer. Cancer Biology & Medicine, 12, 328-341.
[31] Sun, Y., Hu, L., Zheng, H., Bagnoli, M., Guo, Y., Rupaimoole, R., et al. (2015) miR-506 Inhibits Multiple Targets in the Epithelial-to-Mesenchymal Transition Network and Is Associated with Good Prognosis in Epithelial Ovarian Cancer. The Journal of Pathology, 235, 25-36. [Google Scholar] [CrossRef] [PubMed]
[32] Rosso, M., Majem, B., Devis, L., Lapyckyj, L., Besso, M.J., Llauradó, M., et al. (2017) E-Cadherin: A Determinant Molecule Associated with Ovarian Cancer Progression, Dissemination and Aggressiveness. PLOS ONE, 12, e0184439. [Google Scholar] [CrossRef] 
[33] Zhang, F., Luo, B., Wu, Q., Li, Q. and Yang, K. (2022) LncRNA HCG18 Upregulates TRAF4/TRAF5 to Facilitate Proliferation, Migration and EMT of Epithelial Ovarian Cancer by Targeting miR-29a/b. Molecular Medicine, 28, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, L., Zhao, S. and Yu, M. (2019) Mechanism of Low Expression of miR-30a-5p on Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer. DNA and Cell Biology, 38, 341-351. [Google Scholar] [CrossRef] [PubMed]
[35] Gao, F., Wu, Q. and Lu, D. (2024) MicroRNA-10a-5p-Mediated Downregulation of GATA6 Inhibits Tumor Progression in Ovarian Cancer. Human Cell, 37, 271-284. [Google Scholar] [CrossRef] [PubMed]
[36] Peng, D., Wu, T., Wang, J., Huang, J., Zheng, L., Wang, P., et al. (2022) MicroRNA-671-5p Reduces Tumorigenicity of Ovarian Cancer via Suppressing HDAC5 and Hif-1α Expression. Chemico-Biological Interactions, 355, Article 109780. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, C., Li, Y., Zhao, W., Liu, G. and Yang, Q. (2020) Circ-PGAM1 Promotes Malignant Progression of Epithelial Ovarian Cancer through Regulation of the miR-542-3p/CDC5l/PEAK1 Pathway. Cancer Medicine, 9, 3500-3521. [Google Scholar] [CrossRef] [PubMed]

为你推荐